Literature DB >> 16043485

Functional consequences of hypertrophic and dilated cardiomyopathy-causing mutations in alpha-tropomyosin.

Audrey N Chang1, Keita Harada, Michael J Ackerman, James D Potter.   

Abstract

To study the functional consequences of various cardiomyopathic mutations in human cardiac alpha-tropomyosin (Tm), a method of depletion/reconstitution of native Tm and troponin (Tn) complex (Tm-Tn) in cardiac myofibril preparations has been developed. The endogenous Tm-Tn complex was selectively removed from myofibrils and replaced with recombinant wild-type or mutant proteins. Successful depletion and reconstitution steps were verified by SDS-gel electrophoresis and by the loss and regain of Ca2+-dependent regulation of ATPase activity. Five Tm mutations were chosen for this study: the hypertrophic cardiomyopathy (HCM) mutations E62Q, E180G, and L185R and the dilated cardiomyopathy (DCM) mutations E40K and E54K. Through the use of this new depletion/reconstitution method, the functional consequences of these mutations were determined utilizing myofibrillar ATPase measurements. The results of our studies showed that 1) depletion of >80% of Tm-Tn from myofibrils resulted in a complete loss of the Ca2+-regulated ATPase activity and a significant loss in the maximal ATPase activity, 2) reconstitution of exogenous wild-type Tm-Tn resulted in complete regain in the calcium regulation and in the maximal ATPase activity, and 3) all HCM-associated Tm mutations increased the Ca2+ sensitivity of ATPase activity and all had decreased abilities to inhibit ATPase activity. In contrast, the DCM-associated mutations both decreased the Ca2+ sensitivity of ATPase activity and had no effect on the inhibition of ATPase activity. These findings have demonstrated that the mutations which cause HCM and DCM disrupt discrete mechanisms, which may culminate in the distinct cardiomyopathic phenotypes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16043485     DOI: 10.1074/jbc.M505014200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  Myocardial infarction in mice alters sarcomeric function via post-translational protein modification.

Authors:  Benjamin S Avner; Krystyna M Shioura; Sarah B Scruggs; Milana Grachoff; David L Geenen; Donald L Helseth; Mariam Farjah; Paul H Goldspink; R John Solaro
Journal:  Mol Cell Biochem       Date:  2011-12-08       Impact factor: 3.396

Review 2.  The 3-state model of muscle regulation revisited: is a fourth state involved?

Authors:  Sherwin S Lehrer
Journal:  J Muscle Res Cell Motil       Date:  2011-09-25       Impact factor: 2.698

Review 3.  Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all.

Authors:  Thomas E Callis; Brian C Jensen; Karen E Weck; Monte S Willis
Journal:  Expert Rev Mol Diagn       Date:  2010-04       Impact factor: 5.225

Review 4.  Nuclear tropomyosin and troponin in striated muscle: new roles in a new locale?

Authors:  P Bryant Chase; Mark P Szczypinski; Elliott P Soto
Journal:  J Muscle Res Cell Motil       Date:  2013-08-02       Impact factor: 2.698

5.  Enhanced active cross-bridges during diastole: molecular pathogenesis of tropomyosin's HCM mutations.

Authors:  Fan Bai; Adam Weis; Aya K Takeda; P Bryant Chase; Masataka Kawai
Journal:  Biophys J       Date:  2011-02-16       Impact factor: 4.033

6.  The Effect of Tropomyosin Mutations on Actin-Tropomyosin Binding: In Search of Lost Time.

Authors:  William Lehman; Jeffrey R Moore; Stuart G Campbell; Michael J Rynkiewicz
Journal:  Biophys J       Date:  2019-05-13       Impact factor: 4.033

7.  Omecamtiv Mecarbil, a Cardiac Myosin Activator, Increases Ca2+ Sensitivity in Myofilaments With a Dilated Cardiomyopathy Mutant Tropomyosin E54K.

Authors:  Megan S Utter; David M Ryba; Betty H Li; Beata M Wolska; R John Solaro
Journal:  J Cardiovasc Pharmacol       Date:  2015-10       Impact factor: 3.105

8.  Using baculovirus/insect cell expressed recombinant actin to study the molecular pathogenesis of HCM caused by actin mutation A331P.

Authors:  Fan Bai; Hannah M Caster; Peter A Rubenstein; John F Dawson; Masataka Kawai
Journal:  J Mol Cell Cardiol       Date:  2014-04-30       Impact factor: 5.000

9.  ANKRD1, the gene encoding cardiac ankyrin repeat protein, is a novel dilated cardiomyopathy gene.

Authors:  Mousumi Moulik; Matteo Vatta; Stephanie H Witt; Anita M Arola; Ross T Murphy; William J McKenna; Aladin M Boriek; Kazuhiro Oka; Siegfried Labeit; Neil E Bowles; Takuro Arimura; Akinori Kimura; Jeffrey A Towbin
Journal:  J Am Coll Cardiol       Date:  2009-07-21       Impact factor: 24.094

10.  Challenging current paradigms related to cardiomyopathies. Are changes in the Ca2+ sensitivity of myofilaments containing cardiac troponin C mutations (G159D and L29Q) good predictors of the phenotypic outcomes?

Authors:  David Dweck; Nir Hus; James D Potter
Journal:  J Biol Chem       Date:  2008-09-26       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.